Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.51 |
| ▸ | TSPO | P30536 | 2/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 7/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29863082 | 1.00 | HTR6 (0.51) | HTR6TSPOPLA2G2AFABP4PLA2G10 | |
| SCHEMBL27505510 | 0.92 | HTR6 (0.50) | HTR6TSPOFABP4BRD4 | |
| SCHEMBL818425 | 0.92 | HTR6 (0.47) | HTR6PLA2G2AFABP4PLA2G10 | |
| SCHEMBL29862534 | 0.92 | HTR6 (0.47) | HTR6PLA2G2AFABP4PLA2G10 | |
| SCHEMBL27862241 | 0.92 | HTR6 (0.47) | HTR6TSPOPLA2G2APLA2G10 | |
| SCHEMBL6129641 | 0.91 | HTR6 (0.47) | HTR6PLA2G2AFABP4PLA2G10 | |
| SCHEMBL7050807 | 0.91 | HTR6 (0.47) | HTR6TSPOPLA2G2AFABP4PLA2G10 | |
| SCHEMBL6693682 | 0.91 | HTR6 (0.49) | HTR6TSPOPLA2G2AFABP4PLA2G10 | |
| SCHEMBL6129643 | 0.91 | HTR6 (0.47) | HTR6PLA2G2AFABP4PLA2G10 | |
| SCHEMBL6694131 | 0.91 | HTR6 (0.51) | HTR6TSPOPLA2G2AFABP4PLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | LOH ANDREW (US) | 2004-06-10 | — | — | US | claimed |
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | claimed |
| CN-1450893-A | Method for treatment of sepsis | LILLY CO ELI (US) | 2003-10-22 | — | — | CN | claimed |
| EP-0839806-B1 | Substituted tricyclics | LILLY CO ELI (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY | 2003-06-26 | — | — | US | claimed |
| US-20030092767-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | claimed |
| US-6514984-B1 | Human non-pancreatic secretory phospholipase A2 inhibitors | ELI LILLY AND COMPANY | 2003-02-04 | — | — | US | claimed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | claimed |
| CN-1240210-A | Substituted tricyclic compound | LILLY CO ELI (US) | 2000-01-05 | — | — | CN | claimed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | claimed |
| CN-1233176-A | Substituted tricyclics | LILLY CO ELI (US) | 1999-10-27 | — | — | CN | claimed |
| EP-0839806-A1 | Substituted tricyclics | ELI LILLY AND COMPANY (US) | 1998-05-06 | — | — | EP | claimed |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | disclosed |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | OPHIREX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | OPHIREX, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC (US) | 2025-04-15 | — | — | US | disclosed |
| US-6514984-B1 | Human non-pancreatic secretory phospholipase A2 inhibitors | ELI LILLY AND COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0839806-A1 | Substituted tricyclics | ELI LILLY AND COMPANY (US) | 1998-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | PLA2G12A, PLA2G2E, PLA2G3 | HTR6 3251/4885TSPO 4329/4885PLA2G2A 24/4885 |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | HTR6 844/4885TSPO 3208/4885PLA2G2A 11/4885 |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | PLA2G4A, PLA2G12A, PLA2G6 | HTR6 1021/4885TSPO 1862/4885PLA2G2A 4/4885 |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | PLA2G12A, PLA2G3, PLA2G1B | HTR6 2119/4885TSPO 4684/4885PLA2G2A 19/4885 |
| US-20030092767-A1 | Combination therapy for the treatment of inflammatory and respiratory diseases | SERPINB1, ELANE, SPINT2 | HTR6 3778/4885TSPO 4105/4885PLA2G2A 127/4885 |
| US-20030119860-A1 | METHOD FOR TRATMENT OF NON-RHEUMATOID ARTHRITIS | TPP2, PLAAT2, PLAA | HTR6 1473/4885TSPO 2542/4885PLA2G2A 139/4885 |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | PLA2G12A, PLA2G2D, PLAAT2 | HTR6 3030/4885TSPO 4092/4885PLA2G2A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.